Seer inc.

Omid Farokhzad. Founder of 5 different companies, among them: Seer, Inc. (California), Selecta Biosciences, Inc. and DNIB Unwind, Inc. Omid C. Farokhzad is an entrepreneur and is Chairman & Chief Executive Officer for Seer, Inc. (California) (which he founded in 2017). He is also on the board of Placon Therapeutics, Inc.About - SEER Inc. Notwithstanding the hype around AI in recent years, quintessentially its ability to discern patterns and relationships across untenably large and complex datasets is powerful. This clarity allows people to make confident decisions while alleviating cognitive limitations. Cognisant of this and the research that has underpinned ... Mar 3, 2023 · Seer, Inc. (NASDAQ:NASDAQ:SEER) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ETCompany ParticipantsCarrie Mendivil – Investor RelationsOmid... SEER is an authoritative source for cancer statistics in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control ...

REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new …Dr. Langer is the Chair of Seer’s Scientific Advisory Board. He is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents.

Nov 27, 2023 · The average one-year price target for Seer Inc - (NASDAQ:SEER) has been revised to 10.20 / share. This is an increase of 33.33% from the prior estimate of 7.65 dated October 31, 2023. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

The projected annualized growth rate until the end of 2024 for Seer is 17%, significantly lower than the historical growth rate of 62% per year over the past five years. In comparison, other companies in the industry are forecasted to achieve a revenue growth rate of 3.7% per year. 3. Should investors be cautious about Seer?Product and Service Revenue: Seer’s product revenue for the quarter reached $1.8 million, reflecting a 31% decline from $2.6 million in the third quarter of 2022. On the other hand, the company experienced an impressive growth in service revenue, which soared nearly eightfold from $68,000 in the same period last year to $536,000 in Q3 2023.Seer. Manufacturing · California, United States · 118 Employees. Founded in 2017, Seer is a life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease.Seer Inc. Cl A. 3800 Bridge Parkway. Suite 102. Redwood City, California 94065. Phone 1 650 453-0000. Industry Medical Equipment/Supplies. Sector Health Care/Life Sciences.

1 to 50 Employees. 1 Location. Type: Company - Public (SEER) Founded in 2017. Revenue: Unknown / Non-Applicable. Biotech & Pharmaceuticals. Competitors: Unknown. At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes.

Dec 1, 2023 · Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials.

Legal Name Seer, Inc. Stock Symbol NASDAQ:SEER. Company Type For Profit. Contact Email [email protected]. Phone Number (650) 453-0000. Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular ...Seer, Inc. (SEER) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.6700 -0.0100 (-0.60%) At close: 04:00PM ESTSeer Technologies, Inc. | 373 (na) tagasubaybay sa LinkedIn. We are a software consultancy, design, development and managed-services company focused on mobile, cloud and data technologies. In over 11 years, we have worked with enterprises of different sizes and handled a variety of challenging requirements. We are also an Amazon Web …We are pleased to invite you to attend the 2021 Annual Meeting of Stockholders (the Annual Meeting) of Seer, Inc. (Seer or the Company), which will take place on Wednesday, June 16, 2021 at 1:00 p.m. Pacific Time. The Annual Meeting will be held in virtual format this year, in light of the COVID-19 pandemic.REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for …

November 29, 2021 16:05 ET | Source: Seer, Inc. REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new ...C/O SEER, INC. 3800 BRIDGE PARKWAY, SUITE 102 (Street) REDWOOD CITY: CA: 94065 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Seer, Inc. [ SEER] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: 10% Owner: X: Officer (give title below)Third Quarter 2023 Financial Results. Revenue was $4.2 million for the three months ended September 30, 2023, a 5% increase from $4.0 million for the three months ended September 30, 2022. The increase was primarily due to increased instrument sales, services, and grant and other revenue, offset by lower consumables sales.Dec 4, 2020 · This opinion is furnished to you in connection with the Registration Statement on Form S-1 (the “Registration Statement”), filed by Seer, Inc. (the “Company”) with the Securities and Exchange Commission pursuant to Rule 462(b) of the Securities Act in connection with the registration under the Securities Act of 443,356 shares of the …REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and ...Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite ...

Jan 25, 2021 · Item 2.02. Results of Operations and Financial Condition. On January 25, 2021, Seer, Inc. filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a...

Seer, Inc. (the “Issuer”). Item 1(b) Address of Issuer’s Principal Executive Offices. 3800 Bridge Parkway, Suite 102, Redwood City, California 94065 Item 2(a)-(b) Name of Person Filing; Address of Principal Business Office or, if none, Residence. 1. aMoon Growth Fund Limited Partnership (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th ...REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the ...Seer, Inc. · We aim to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological ...SC 13G 1 seer-13gof12x31x20214875x3.htm SC 13G UNITED STATES . SECURITIES AND EXCHANGE COMMISSION . Washington, D.C. 20549 ...Proteomics analysis just got easier. Quickly and accurately analyze your data, investigate complex biology, and discover new biomarkers with Seer’s powerful, easy-to-use Proteograph™ Analysis Suite.Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling.Dr. Farokhzad is a physician-scientist, serial entrepreneur, company founder, company builder, executive and director – across multiple companies and technology platforms. He founded Seer, Inc. (Nasdaq: SEER) in 2017, which advances a transformative proteomics platform, and serves as Founder, CEO and Chair.

Seer, Inc. Fourth Quarter 2021 Earnings Conference Call. Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook. Form 10-K.

Director, Commercial Operations. Joined Seer August 2022. LinkedIn. Margaret Donovan. Our highly collaborative and high-energy environment has allowed Seer to become a leader in proteomics, and I'm excited to be a part of that journey. After joining Seer directly out of graduate school as a bioinformatician, I have been lucky to be supported by ...

Sep 30, 2022 · Third Quarter 2022 Financial Results. Revenue was $4.0 million for the three months ended September 30, 2022, as compared to $2.2 million for the three months ended September 30, 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. Product-related revenue for the third quarter of ... Serafim Batzoglou is currently affiliated with Seer, Inc. Heidi Rehm receives funding to support rare disease research and tool development from Illumina, Inc. and Microsoft, Inc. To systematically decipher the effects of human genetic variants, we obtained whole genome sequencing data for 809 individuals from 233 primate species, and ...Seer, Inc. (SEER 4.97%) Q4 2021 Earnings Call Feb 28, 2022, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good day, and thank you ...Dec 16, 2021 · Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021. The ICE Biotechnology Index tracks the performance of qualifying …2.7“Company” means Seer, Inc., a Delaware corporation, or any successor thereto. 2.8 “ Company Group ” means the Company and any Parents, Subsidiaries, and Affiliates. 2.9 “ Disability ” means a permanent and total disability determined in accordance with uniform and nondiscriminatory standards adopted by the Administrator from time ...The Board of Directors of Seer, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's ... Mondelez International Inc Class A. MDLZ Conagra Brands Inc. CAG Nestle SA ADR. NSRGY Valuation . View More. Metric HSY MDLZ CAG Price/Earnings (Normalized) 19.60: 21.60: 9.93: Price/Book Value.Seer Employee Directory. Seer corporate office is located in 3800 Bridge Pkwy Ste 102, Redwood City, California, 94065, United States and has 242 employees. seer inc. seer technologies inc. seer technology inc. …It is so pleasant to work with experts. Click here to find out more regarding ConEd., In case you're interested in knowing more info on business cards acn, stop by ...Kogan led the legal and government affairs functions of Avanir Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from May 2011 to August 2015, until its acquisition by Otsuka Pharmaceutical Co. Ltd. Prior roles included positions of increasing responsibility at King Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bergen Brunswig ...REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the ...Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite ...

Product and Service Revenue: Seer’s product revenue for the quarter reached $1.8 million, reflecting a 31% decline from $2.6 million in the third quarter of 2022. On the other hand, the company experienced an impressive growth in service revenue, which soared nearly eightfold from $68,000 in the same period last year to $536,000 in Q3 2023.See the latest Seer Inc Ordinary Shares - Class A stock price (SEER:XNAS), related news, valuation, dividends and more to help you make your investing ...Seer, Inc. (Exact name of registrant as specified in its charter) Delaware: 001-39747: 82-1153150 (State or other jurisdiction of (Commission (I.R.S. Employer: incorporation) File Number) Identification No.) 3800 Bridge Parkway, Suite 102. Redwood City, California 94065Instagram:https://instagram. will delta dental cover veneershydrogen power stocksmercedes amg gle 63 snvda stock stocktwits Aug 14, 2023 · SEER*Stat is a statistical software that calculates raw data of cancer statistics, rates, and trends. The SEER*Stat statistical software provides a convenient, intuitive mechanism for the analysis of SEER and other cancer-related databases. It is a powerful PC tool to view individual cancer records and to produce statistics for studying … sandp 500 additions and deletions 2023epic corp C/O SEER, INC. 3800 BRIDGE PARKWAY, SUITE 102 (Street) REDWOOD CITY: CA: 94065 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Seer, Inc. [ SEER] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director: 10% Owner: X: Officer (give title below)Seer, Inc. (NASDAQ:NASDAQ:SEER) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ETCompany ParticipantsCarrie Mendivil - IROmid Farokhzad -... avav stock price Sep 30, 2022 · Third Quarter 2022 Financial Results. Revenue was $4.0 million for the three months ended September 30, 2022, as compared to $2.2 million for the three months ended September 30, 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. Product-related revenue for the third quarter of ... Seer, Inc. (Name of Issuer) Class A Common Stock, $0.00001 par value per share (Title of Class of Securities) 81578P 106 (CUSIP Number) Mark Gurevich . Maverick Capital, Ltd. 1900 N. Pearl Street, 20 th Floor . Dallas, TX 75201 (214) 880-4000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) …